"Simvastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.
| Descriptor ID |
D019821
|
| MeSH Number(s) |
D02.455.426.559.847.638.400.900 D04.615.638.400.900
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Simvastatin".
Below are MeSH descriptors whose meaning is more specific than "Simvastatin".
This graph shows the total number of publications written about "Simvastatin" by people in this website by year, and whether "Simvastatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1998 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 3 | 1 | 4 |
| 2004 | 3 | 1 | 4 |
| 2005 | 2 | 2 | 4 |
| 2006 | 5 | 1 | 6 |
| 2007 | 6 | 1 | 7 |
| 2008 | 2 | 3 | 5 |
| 2009 | 4 | 1 | 5 |
| 2010 | 3 | 1 | 4 |
| 2011 | 5 | 1 | 6 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 3 | 5 |
| 2014 | 3 | 0 | 3 |
| 2015 | 3 | 1 | 4 |
| 2016 | 3 | 3 | 6 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Simvastatin" by people in Profiles.
-
Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: a pilot study. J Obstet Gynaecol. 2022 Aug; 42(6):2139-2143.
-
SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemp Clin Trials. 2021 05; 104:106367.
-
Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization. Mol Carcinog. 2019 07; 58(7):1118-1133.
-
Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery. J Pharm Biomed Anal. 2019 Feb 05; 164:258-267.
-
The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care. Contemp Clin Trials. 2018 12; 75:40-50.
-
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
-
Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project. JAMA Intern Med. 2017 06 01; 177(6):887-889.
-
Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. Hypertension. 2017 02; 69(2):314-322.
-
Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines. Am Heart J. 2016 Dec; 182:97-102.
-
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96.